IL17A and acquired polycythemia vera: Ixekizumab, recognized as an effective biomedical treatment targeting IL-17A, is internationally approved in the treatment of PV (Menter et al., 2019; Chinese Society of Dermatology, 2021) and is recommended as the first-line therapy for severe PV in published guideline (Nast et al., 2021).